Aberdeen Group
SPRY icon

Aberdeen Group’s ARS Pharmaceuticals SPRY Stock Holding History

Aberdeen Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.4M Buy
4,170,629
+57,012
+1% +$490K 0.05% 310
2026
Q1 		$33M Buy
4,113,617
+557,568
+16% +$5.34M 0.05% 290
2025
Q4 		$41.4M Buy
3,556,049
+459,027
+15% +$4.46M 0.06% 252
2025
Q3 		$31.1M Buy
3,097,022
+1,594,447
+106% +$22.9M 0.05% 303
2025
Q2 		$26.2M Buy
1,502,575
+499,916
+50% +$7.21M 0.04% 335
2025
Q1 		$12.6M Buy
+1,002,659
New +$12.1M 0.02% 511

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Aberdeen Group's SPRY Position: Q2 2026 in Review

Aberdeen Group increased its ARS Pharmaceuticals (SPRY) stake by 1.4% in Q2 2026, buying an estimated $490K and bringing the position to 4,170,629 shares worth $33.4M. The position accounts for 0.05% of the portfolio, ranked #310.

Aberdeen Group first reported a position in SPRY in Q1 2025 and has held it in 6 quarters since. The position peaked at $41.4M in Q4 2025. 206 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Aberdeen Group held 4,170,629 shares of ARS Pharmaceuticals worth $33.4M as of Q2 2026.
  • Aberdeen Group bought 57,012 ARS Pharmaceuticals shares in Q2 2026, an estimated $490K.
  • ARS Pharmaceuticals made up 0.05% of Aberdeen Group's portfolio in Q2 2026, its #310 holding.
  • Aberdeen Group first reported a position in ARS Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • Aberdeen Group's ARS Pharmaceuticals position peaked at $41.4M in Q4 2025.
  • 206 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.